Esperienza di terapia con CAR-T axi-cel in paziente anziano, affetto da DLBCL double expressor in stadio avanzato e refrattario a chemio-immunoterapia di prima linea

We hereby describe a case of successful therapy with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor T-cells (CAR-T) in an elderly patient suffering from DLBCL refractory to first-line chemoimmunotherapy, with particular reference to the setting of the diagnostic/therapeutic path and collaboration between the Referral center and the CAR-T center.